The time frame would have to be uncertain because Juniper only had partial success after a lot of work. At least it was sufficient to enable some preliminary trials, but for the time and money spent, a big let down. Poor palatability restricts dosage, which restricts effectiveness, and therefore restricts full trial testing, so they're all interlinked, unfortunately.
Ann: Appendix 4C - Quarterly Report & Brief Company Update, page-29
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.8¢ |
Change
-0.003(1.25%) |
Mkt cap ! $87.89M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.8¢ | 19.5¢ | $29.82K | 151.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 506946 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 803554 | 8 |
View Market Depth
| Last trade - 11.53am 10/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |